证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-048 迪瑞医疗科技股份有限公司 关于持股 5%以上股东及一致行动人减持股份比例达到 1% 暨提前终止减持计划的公告 持股 5%以上的股东宋洁、宋勇、易湘苹保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 迪瑞医疗科技股份有限公司（以下简称"迪瑞医疗"或"公司"）2024 年 10 月 27 日披露了《关于持股 5%以上股东减持股份预披露公告》。"持股 5%以上股 东宋洁女士及其一致行动人宋勇先生、易湘苹女士（上述股东合计持有公司股份 36,853,103 股，占公司总股本比例 13.51%)计划自本减持计划公告之日起十五个 交易日后的三个月内（即 2024 年 11 月 19 日至 2025 年 2 月 18 日）以竞价或大 宗交易方式减持公司股份合计不超过 5,410,000 股，减持股份数量不超过公司目 前总股本 1.98%。其中，通过竞价方式减持的，宋洁及一致行动人任意连续 90 个自然日内以竞价方式减持股份的总数不超过公司股份总数的 1 ...

Investment Rating - The report maintains a "Recommend" rating for Dirui Medical (300396) with a target price of 22 CNY, compared to the current price of 17.28 CNY [1] Core Views - Dirui Medical's performance is under temporary pressure, with a focus on the installation of high-speed machines and the increase in the sales proportion of reagent products [2] - The company's domestic business in Q3 2024 focused on basic medical instruments, leading to a decline in gross margin due to product structure and medical procurement policies [2] - Overseas business is recovering as planned, with some localization projects already operational, shortening the reagent supply cycle and reducing transportation costs [2] - The company plans to accelerate the installation of high-speed machines and promote balanced development of instruments and reagents to ensure stable growth [2] - Comprehensive cost control measures have achieved initial results, with a significant decrease in management expenses by 51.80% in Q3 2024 [2] - Product registration is progressing steadily, with 4 medical device change registration documents and 22 medical device registration certificates obtained in August 2024, enhancing the company's product competitiveness [2] Financial Performance - In Q1-Q3 2024, Dirui Medical's revenue was 1.175 billion CNY (+12.10% YoY), with net profit attributable to shareholders of 193 million CNY (-17.80% YoY) [1] - In Q3 2024, revenue was 297 million CNY (-15.97% YoY), with net profit attributable to shareholders of 27 million CNY (-62.28% YoY) [1] - The company's sales expenses in Q3 2024 were 54 million CNY (-0.60% YoY), R&D expenses were 33 million CNY (-4.64% YoY), and management expenses were 9 million CNY (-51.80% YoY) [2] - The management expense ratio in Q3 2024 was 3.16%, a decrease of 2.34 percentage points [2] Financial Forecast - The report forecasts Dirui Medical's net profit attributable to shareholders for 2024-2026 to be 280 million, 380 million, and 520 million CNY, with YoY growth rates of +2.2%, +35.5%, and +35.8% respectively [2] - EPS for 2024-2026 is expected to be 1.03, 1.40, and 1.90 CNY, with corresponding P/E ratios of 17x, 12x, and 9x [2] - The DCF model estimates the company's overall valuation at 6 billion CNY, corresponding to a target price of 22 CNY [2] Market Performance - Dirui Medical's total market capitalization is 4.712 billion CNY, with a circulating market capitalization of 4.708 billion CNY [4] - The company's 12-month high and low prices are 32.80 CNY and 12.92 CNY respectively [4] Product and Market Strategy - The company is focusing on the localization of overseas markets, with some projects already operational, which is expected to improve the proportion of reagent sales in international markets [2] - Dirui Medical is advancing the development of high-speed machines and reagent products, aiming to optimize its product structure and enhance market competitiveness [2]

Summary of the Conference Call Industry or Company Involved - The conference call pertains to the **Jilin Province listed companies** and their efforts to enhance investor confidence through an online collective reception day event in 2025 [1][10]. Core Points and Arguments - The event is organized by the **Jilin Securities Industry Association** in collaboration with **Shenzhen Panorama Network Co., Ltd.**, aimed at improving the intellectual level of listed companies in Jilin and establishing a good communication mechanism between companies and investors [1][10]. - High-level executives from various listed companies, including chairpersons, general managers, financial directors, and board secretaries, participated in the online interaction with investors, addressing concerns regarding the **2024 annual reports**, risk prevention, investor protection, and sustainable development [1][10]. - The event utilized internet virtual space for face-to-face communication, allowing investors to gain a comprehensive understanding of the participating companies [3][10]. - A total of **872 questions** were answered by company representatives during the event, indicating a strong interaction between listed companies and investors [10]. Other Important but Possibly Overlooked Content - The event emphasizes the importance of maintaining open channels for communication between listed companies and investors, suggesting that the interaction will continue beyond the event through platforms like **Panorama Network** [10]. - The initiative reflects a broader trend in the industry towards enhancing transparency and responsiveness to investor inquiries, which is crucial for building trust and confidence in the market [1][10].

证券时报e公司讯，迪瑞医疗(300396)10月27日晚间公告，股东宋洁及其一致行动人宋勇、易湘苹计划 自十五个交易日后的三个月内（即2024年11月19日至2025年2月18日）以竞价或大宗交易方式减持公司 股份合计不超过541万股，减持股份数量不超过公司目前总股本1.98%。 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-047 迪瑞医疗科技股份有限公司 关于持股 5%以上股东减持股份预披露公告 持股 5%以上的股东宋洁、宋勇、易湘苹保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 迪瑞医疗科技股份有限公司（以下简称"公司"）持股 5%以上股东宋洁女 士及其一致行动人宋勇先生、易湘苹女士(上述股东合计持有公司股份 36,853,103 股，占公司总股本比例 13.51%)计划自本减持计划公告之日起十五 个交易日后的三个月内（即 2024 年 11 月 19 日至 2025 年 2 月 18 日）以竞价或 大宗交易方式减持公司股份合计不超过 5,410,000 股，减持股份数量不超过公 司目前总股本 1.98%。其中，通过竞价方式减持的，宋洁及一致行动人任意连续 90 个自然日内以竞价方式减持股份的总数不超过公司股份总数的 1%；通过大宗 交易方式减持的，宋洁及一致行动人任意连续 90 个自然日内以大宗交易方式减 持股份的总数不超过公司股份总数的 2% ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-042 迪瑞医疗科技股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届董事会第四次会议 （以下简称"本次会议"）于 2024 年 10 月 24 日在公司以现场及通讯方式召开， 本次会议由董事长宋清先生主持，应出席公司会议的董事 9 人，实际出席董事 9 人，公司监事、高级管理人员列席会议。根据《公司章程》的规定，本次会议通 知于 2024 年 10 月 14 日以现场及电子邮件送达方式发出，会议召开符合《中华 人民共和国公司法》《公司章程》的规定，会议合法有效。 与会董事经认真审议，以现场或通讯表决方式审议通过了如下决议： 一、审议并一致通过《2024 年第三季度报告》 公司《2024 年第三季度报告》的编制程序符合法律、行政法规和中国证监会 的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在虚假记载、 误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。 由于公司部分业务主要 ...

关于开展远期外汇交易及外汇期权业务的可行性分析报告 一、交易的背景与目的 由于迪瑞医疗科技股份有限公司（以下简称"公司"）部分业务主要采用美 元等外币进行结算，为减少汇率波动带来的风险，公司及控股子公司拟开展远期 外汇交易及外汇期权业务。公司及控股子公司开展前述业务，将遵循稳健原则， 不进行以投机和盈利为目的的外汇交易，所有远期外汇交易及外汇期权业务均以 正常生产经营为基础，以规避和防范汇率风险为目的，不影响公司主营业务的发 展。 二、交易的基本情况 迪瑞医疗科技股份有限公司 可能会存在的风险，公司制定了《外汇套期保值业务管理制度》，完善了相关内 控制度，公司采取的针对性风险控制措施是切实可行的。因此，公司及控股子公 司开展远期外汇交易及外汇期权业务具有一定的必要性和可行性。 四、远期外汇交易及外汇期权业务的风险分析及公司采取的风险控制措施 （一）远期外汇交易及外汇期权业务的风险分析 公司及控股子公司开展远期外汇交易及外汇期权业务遵循合法、谨慎、安全 和有效的原则，不做投机性、套利性的交易操作，远期外汇交易及外汇期权业务 可以在汇率发生大幅波动时，降低汇率波动对公司的影响，使公司专注于生产经 营，但远期外汇交 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-043 具体内容详见巨潮资讯网（www.cninfo.com.cn）《2024年第三季度报告》。 表决结果：3 票同意，0 票反对，0 票弃权，同意票占有效表决权 100%。 迪瑞医疗科技股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届监事会第四次会议 （以下简称"本次会议"）于 2024 年 10 月 24 日在公司以现场及通讯方式召开， 本次会议由监事会主席熊玲霞主持，应出席公司会议的监事 3 人，实际出席公司 会议的监事 3 人。根据《公司章程》的规定，本次会议通知于 2024 年 10 月 14 日以现场送达及通讯方式发出，会议召开符合《中华人民共和国公司法》、《公司 章程》的规定，会议合法有效。 与会监事经认真审议，以现场表决方式审议通过了如下决议： 一、审议并一致通过《2024年第三季度报告》 经审核，监事会认为董事会编制和审核公司《2024年第三季度报告》的程序 符合法律、行政法规和中国证 ...

Revenue and Profit - Revenue for Q3 2024 was ¥297,174,611.23, a decrease of 15.97% year-over-year, while year-to-date revenue reached ¥1,175,445,053.92, an increase of 12.10%[2] - Net profit attributable to shareholders for Q3 2024 was ¥27,334,486.91, down 62.28% year-over-year, with year-to-date net profit at ¥192,577,440.82, a decrease of 17.80%[2] - Basic and diluted earnings per share for Q3 2024 were both ¥0.1002, reflecting a decline of 62.47% compared to the same period last year[2] - The net profit for Q3 2024 was approximately ¥192.57 million, a decrease of 17.7% compared to ¥234.27 million in Q3 2023[17] - The total operating profit was ¥214.11 million, down 16.5% from ¥256.42 million in Q3 2023[17] - The company reported a total comprehensive income of ¥193.43 million, a decrease of 16.6% from ¥231.88 million in the previous year[18] Assets and Liabilities - The company's total assets as of the end of Q3 2024 were ¥3,070,950,229.04, a decrease of 7.52% from the end of the previous year[2] - Total assets decreased to ¥3,070,950,229.04 from ¥3,320,764,441.14, a reduction of 7.5%[15] - Total liabilities decreased to ¥974,554,696.64 from ¥1,281,453,034.50, a decline of 23.9%[15] - The equity attributable to shareholders increased to ¥2,096,375,860.39, up from ¥2,039,281,003.59, a growth of 2.8%[15] Cash Flow - Cash flow from operating activities showed a net outflow of ¥299,371,952.53, representing a significant decline of 637.22% year-over-year[2] - The net cash flow from operating activities was negative at ¥299.37 million, compared to a positive cash flow of ¥55.73 million in Q3 2023[19] - The company’s investment activities generated a net cash inflow of ¥7.52 million, a significant decrease from ¥61.08 million in the previous year[20] - The company reported a net investment income of ¥20,686,292.54, down from ¥26,911,000.18, a decrease of 23.1%[16] Accounts Receivable and Inventory - The company reported a 36.78% increase in accounts receivable compared to the beginning of the period, amounting to an increase of ¥158,953,600[5] - Accounts receivable increased to ¥591,080,039.40, up 36.8% from ¥432,126,395.59 at the beginning of the period[13] - Inventory decreased to ¥492,717,834.54, down 13.9% from ¥572,935,454.69[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,095[8] - The largest shareholder, Shenzhen Huadexin Run Equity Investment Enterprise, holds 28.34% of shares, totaling 77,288,400 shares[8] - Guangdong Hengjian International Investment Co., Ltd. holds 12.15% of shares, totaling 33,123,600 shares[8] - The number of shares held by the top ten shareholders includes significant stakes from individual shareholders, such as Song Jie with 6.32%[8] - The company has not disclosed any related party relationships among the top shareholders[9] Stock Repurchase and Capital Changes - The company repurchased and canceled 132,547 restricted stocks due to unmet conditions for the first release period of the 2022 restricted stock incentive plan[11] - A total of 1,865,750 restricted stocks were repurchased and canceled due to unmet conditions for the 2021 and 2022 restricted stock incentive plans[12] - The company's total share capital has changed to 274,565,911 shares after the cancellation of restricted stocks[11] - The company’s registered capital has changed to 272,700,161 yuan after the cancellation of restricted stocks[12] - The total number of restricted shares at the beginning of the period was 19,562,663, with 17,345,325 released during the period[10] Expenses - Total operating costs amounted to ¥986,818,603.55, up 18.3% from ¥834,307,086.89 year-over-year[16] - Research and development expenses were ¥95,643,187.59, reflecting an increase of 12.5% compared to ¥85,343,396.06 in the previous year[16] - Management expenses decreased by ¥17,268,200, down 33.49% year-over-year, due to cost control measures and optimization of functional systems[6] Credit and Impairment - The company experienced a 400.20% increase in credit impairment losses, amounting to an increase of ¥9,508,100, due to an increase in accounts receivable and higher bad debt provisions[6] Cash and Equivalents - The company's cash and cash equivalents decreased to ¥471,019,852.83 from ¥845,730,745.23, a decline of 44.4%[13] - The cash and cash equivalents at the end of the period were ¥459.57 million, a decrease from ¥756.52 million at the end of Q3 2023[20] Foreign Exchange - The company recorded a foreign exchange gain of ¥867,496.48, compared to a loss of ¥2.38 million in the same quarter last year[18]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-045 迪瑞医疗科技股份有限公司 关于开展远期外汇交易及外汇期权业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、交易种类：远期外汇交易及外汇期权业务。 2、交易金额：额度不超过 13,000 万元人民币（或等值外币），在上述额度 范围内，资金可循环使用。 3、特别风险提示：公司开展远期外汇交易及外汇期权业务遵循合法、谨慎、 安全和有效的原则，不做投机性、套利性的交易操作，但外汇套期保值业务操作 仍存在汇率波动、交易违约及其它风险，公司将采取相应措施控制风险。敬请广 大投资者注意投资风险。 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届董事会第四次会议 及第六届监事会第四次会议审议通过了《关于开展远期外汇交易及外汇期权业务 的议案》，同意公司及控股子公司使用自有资金开展额度不超过人民币 13,000 万 元（或等值外币）的远期外汇交易及外汇期权业务，根据相关法律、法规、规章、 规范性文件以及《公司章程》的相关规定，有效期限自董事会审议通过之日起十 二个月内有效，在 ...